"Pablo's broad leadership and management skills, combined with his track record of developing some of the most successful cancer therapies, including Tarceva, Afinitor, and Folotyn, make him the ideal person to lead our efforts in the development of innovative oncology medicines," said Dr. Coles. "He brings world-class R&D leadership as Onyx delivers on its vision of becoming a leading global oncology company committed to bringing new therapies to patients living with cancer."
Prior to joining the company, Dr. Cagnoni was senior vice president and Global Head of Clinical Development of Novartis Oncology. He was responsible for all clinical development, clinical operations, clinical pharmacology and science activities for the oncology development pipeline. He oversaw the U.S., European and Japanese regulatory submissions and approvals of Afinitor, Tasigna, Signifor, Exjade, Jakavi and Glivec in various indications.